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Introduction: We previously reported that most patients with rheumatoid arthritis (RA) and moderate
cardiovascular disease (CVD) risk according to the Systematic COronary Evaluation score (SCORE) experience carotid
artery plaque. In this study, we aimed to identify patient characteristics that can potentially predict carotid plaque
presence in women with RA and a concurrent low CVD risk according to the SCORE.
Methods: A cohort of 144 women with an evaluated low risk of CVD (SCORE value of zero) was assembled
amongst 550 consecutive patients with RA that underwent CVD risk factor recording and carotid artery ultrasound.
Participants had no established CVD, moderate or severe chronic kidney disease, or diabetes. We assessed carotid
plaque(s) presence and its associated patient characteristics.
Results: Carotid artery plaque was present in 35 (24.3%) of women with RA. Age, the number of synthetic
disease-modifying agents (DMARDs) and total cholesterol concentrations were independently associated with
plaque in multivariable stepwise backward regression analysis (odds ratio (95% confidence interval) = 1.15 (1.07 to
1.24), P <0.0001, 1.51 (1.05 to 2.17), P = 0.03 and 1.66 (1.00 to 2.73) P = 0.04), respectively). The area under the curve
(AUC) of the receiver operating curve (ROC) for the association with plaque was 0.807 (P <0.0001), 0.679 (P = 0.001)
and 0.599 (P = 0.08) for age, total cholesterol concentrations and number of synthetic DMARDs used, respectively.
The optimal cutoff value in predicting plaque presence for age was 49.5 years with a sensitivity and specificity
of 74% and 75%, respectively, and for total cholesterol concentration, it was 5.4 mmol/l with a sensitivity and
specificity of 63% and 70%, respectively. The plaque prevalence was 37.5% in patients (n = 80; 55.6%) with
age >49.5 years or/and total cholesterol concentration of >5.4 mmol/l, respectively, compared to only 7.8% in
those (n = 64; 44.4%) with age ≤49.5 years or/and total cholesterol concentration of ≤5.4 mmol/l, respectively.
Conclusions: Approximately one-third of women with RA who experience a low SCORE value and are aged >49.5
years or/and have a total cholesterol concentration of >5.4 mmol/l, experience high-risk atherosclerosis, which
requires intensive CVD risk management.* Correspondence: dessein@telkomsa.net
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that enhances the risk of atherosclerotic cardiovascu-
lar event rates to a similar extent as type 2 diabetes [1].
Traditional risk factors do not fully explain the increased
cardiovascular disease (CVD) risk in RA [2]. In fact, trad-
itional risk factors and disease characteristics, in particular
high-grade inflammation, associate overall additively and
as strongly with atherosclerosis and incident CVD event
rates in RA [3-5].
The EUropean League Against Rheumatism (EULAR)
recently reported recommendations for CVD risk manage-
ment in inflammatory arthritis including RA [1]. This com-
prised risk stratification based on the Systematic COronary
Evaluation Score (SCORE), a multiple major traditional
risk factor equation, together with the use of a multiplier
of 1.5 when two of three criteria were met; the latter con-
sisted of a disease duration >10 years, rheumatoid factor
or/and anticyclic citrullinated peptide positivity and the
presence of severe extra-articular manifestations, thereby
providing a modified (m) SCORE in patients with RA.
However, the mSCORE can underestimate the actual CVD
risk in patients with RA [6,7].
Carotid artery plaque as identified by ultrasound repre-
sents very high CVD risk [8,9] and indeed strongly pre-
dicts incident cardiovascular event rates in both non-RA
and RA subjects [8-10]. Accordingly, the recent European
CVD prevention guidelines [8] recommend risk man-
agement that includes the use of cardiovascular drugs,
as in secondary prevention, with a low-density lipopro-
tein (LDL) cholesterol target of <1.8 mmol/l, in persons
with carotid artery plaque [8]. Carotid ultrasound is par-
ticularly indicated in non-RA subjects at moderate riskFigure 1 Flowchart of patients included in the study. CKD, chronic kidn
Systematic COronary Risk Evaluation; n, number.of CVD [8]. In this regard, we recently documented that
amongst RA patients with an mSCORE value of ≥1 and <5
that reflects moderate CVD risk, as many as 63% had ca-
rotid artery plaque [11].
Advancing age contributes substantially to calculated
mSCORE values in individual persons [1,8] whereas dis-
ease characteristics rather than traditional risk factors
are reportedly most strongly associated with atheroscler-
osis, especially in young patients with RA [12]. It is there-
fore conceivable, and was indeed confirmed, that in
patients with RA and a concurrent low predicted cardio-
vascular event rate as estimated by SCORE, that is, when
the respective calculated value is zero, atherosclerosis that
represents high CVD risk can be present [11]. Phenotypic
characterization of such patients is required in determin-
ing which of these can benefit from carotid ultrasound in
an attempt to enhance their CVD stratification or/and
more intensive cardiovascular risk factor management. In
the present study, we therefore aimed to identify patient
characteristics that can predict potential plaque presence
in a relatively large cohort of women with RA and a con-
current low CVD risk according to the SCORE.
Methods
Patients
A total of 150 patients with RA and a SCORE of zero
were recruited at the Hospital Universitario Marques de
Valdecilla in Santander, Spain. As shown in Figure 1, par-
ticipants originated in a group of 550 consecutive patients
without established CVD (ischemic heart disease, cerebro-
vascular accident, peripheral arterial disease or/and heart
failure) that underwent cardiovascular risk factor record-
ing and carotid ultrasound as previously reported [11]. Iney disease; CVD, cardiovascular disease; (m) SCORE, (modified)
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diabetes, type 2 diabetes and moderate (estimated glom-
erular filtration rate = 30 to 59 ml/min/1.73 m2) or severe
chronic kidney disease (estimated glomerular filtration
rate <30 ml/min/1.73 m2) as these comorbidities represent
high or very high CVD risk [8,11]. All patients in our on-
going study on CVD risk in RA meet the 1987 American
College of Rheumatology [13] as well as the 2010 classifi-
cation criteria for RA [14]. As all patients were enrolled at
the same single center (see above), ethics’ approval was re-
quired and hence obtained from the Ethics Committee of
Cantabria for Hospital Universitario de Valdecilla in
Santander (Spain), and not from the other centers that
some of the authors belonged to. Each participant gave
written informed consent.
Cardiovascular risk factors
Recorded patient characteristics are shown in Table 1.
Conventional CVD risk factors were defined using previ-
ously reported methods by us [15]. Based on age, sex,
smoking status, systolic blood pressure, total cholesterol
and high-density lipoprotein (HDL) cholesterol concentra-
tions, the SCORE was calculated to determine the 10-year
risk of fatal CVD in a European population at low CVD
risk, as recommended in persons living in Spain [8,11].
Since only patients with a SCORE of zero were included in
the present study, calculation of the mSCORE as recom-
mended by EULAR in RA patients [1], was not performed.
Recorded cardiovascular drugs included antihyperten-
sive agents and statins. Extra-articular manifestations
comprised nodular disease, Felty’s syndrome, pulmonary
fibrosis, rheumatoid vasculitis and secondary Sjogren’s
syndrome [11].
Carotid ultrasound
Arterial atherosclerotic plaques in the extracranial carotid
tree were identified using the commercially available scan-
ner, Mylab 70 Esaote (Genoa, Italy) equipped with a 7 to 12
MHz linear transducer and the automated software-guided
technique radio frequency-Quality Intima Media Thickness
in real-time (QIMT, Esaote, Maastricht, The Netherlands)
was used [11]. Carotid artery plaque was identified as rec-
ommended in the Mannheim consensus, that is when a
focal structure that encroaches into the arterial lumen of at
least 0.5 mm or 50% of the surrounding intima-media
thickness (IMT) value or demonstrates a thickness of >1.5
mm as measured from the media-adventitia interface of the
intima-lumen interface, is present [16].
All assessments were made on the same day in each
patient.
Data analysis
Results are expressed as mean (standard deviation
(SD)), median (range) or proportions as appropriate.The associations of recorded patient characteristics with
plaque were first assessed using univariate logistic re-
gression models; characteristics that were found to be
related to atherosclerosis were subsequently entered in
a multivariable stepwise backward conditional logistic
regression model.
For characteristics that were independently associated
with atherosclerosis, sensitivity versus false positive fre-
quency (1-specificity) for predicting plaque presence
was analyzed employing receiver operating characteris-
tic (ROC) curves. The predictive accuracy of recorded
characteristics was evaluated by the area under the
curve (AUC). To determine the optimal cutoff value of
baseline characteristics in predicting plaque presence,
we calculated the Youden index using the following
formula: sensitivity + specificity – 1, with the maximum
obtained value corresponding to the optimal cutoff point
[17]. We also calculated the negative and positive predict-
ive values based on Bayes’ theorem as follows: positive
predictive value = prevalence (p) x sensitivity/[p x sensi-
tivity + (1 - p) × specificity] and negative predictive
value = (1 - p) × specificity / [p x (1 - sensitivity) + (1 - p) ×
specificity] [18].
Statistical computations were made using the GB Stat
program (Dynamic Microsystems, Inc., Silver Spring, MD,
USA) and SPSS software, version 21 (IBM Corp., Armonk,
NY, USA).
Results
Of the initially recruited 150 patients with a SCORE of
zero, 144 (96%) were women (Figure 1), 35 (24.3%) of
whom had carotid artery plaque that was unilateral and
bilateral in 21 (60%) and 14 (40%) of them, respectively.
A carotid IMT of >0.900 mm was observed in only one
(0.7%) patient who further had concurrent plaque. As
none of the six participating men had carotid plaque,
these were excluded from subsequent analysis. Amongst
female participants, mean (SD) age and RA duration were
44.8 (11.7) and 8.2 (7.7) years, respectively. All except four
patients had received synthetic disease-modifying anti-
rheumatic drugs (DMARDs).
Recorded characteristics in patients with and without
carotid plaque
Table 1 gives potential CVD risk factors in patients with
and without carotid plaque. Patients with carotid plaque
were older and experienced later disease onset, sustained
more prevalent hypertension and dyslipidemia and larger
total and LDL cholesterol and triglyceride concentrations,
and were more frequently treated with cardiovascular
drugs. Blood pressure control was poorer in patients with
carotid plaque, and none of them had adequate lipid con-
trol (LDL cholesterol <1.8 mmol/l) [8]. With regard to RA
characteristics, patients with carotid plaque had larger
Table 1 Recorded characteristics and their associations with plaque in 144 patients with a SCORE of zero
Plaque
Characteristics Absent Present
(n = 109) (n = 35) OR (95% CI) P
Demographic
Age (years) 42.4 (9.5) 52.1 (5.7) 1.17 (1.09-1.25) <0.0001
Conventional CV risk factors
Hypertension 14.7 31.4 2.66 (1.09-6.53) 0.01
Systolic blood pressure (mmHg) 120 (13) 127 (16) 1.04 (1.01-1.07) 0.01
Diastolic blood pressure (mmHg) 76 (8) 78 (7) 1.04 (0.99-1.10) 0.09
Dyslipidemia 22.0 40.0 2.36 (1.04-5.37) 0.04
Total cholesterol (mmol/l) 5.0 (0.9) 5.5 (0.9) 1.80 (1.19-2.74) 0.006
LDL cholesterol (mmol/l) 2.9 (0.8) 3.2 (0.7) 1.01 (1.00-1.03) 0.03
HDL cholesterol (mmol/l) 1.7 (0.9-4.1) 1.7 (1.0-4.1) 1.01 (0.99-1.03) 0.4
Cholesterol-HDL cholesterol ratio 2.9 (1.5-5.7) 3.0 (1.9-5.7) 1.36 (0.85-2.18) 0.2
Triglycerides (mmol/l) 0.8 (0.4-2.2) 0.8 (0.4-4.3) 1.01 (1.00-1.02) 0.04
Triglyceride-HDL cholesterol ratio 1.0 (0.4-5.5) 1.1 (0.3-10.0) 1.28 (0.91-1.82) 0.1
Smoking ever 53.2 54.3 1.04 (0.48-2.26) 0.9
Current smoking 31.2 28.6 0.88 (0.38-2.05) 0.8
Body mass index (kg/m2) 24.4 (15.2-48.7) 24.7 (18.4-48.2) 1.06 (1.00-1.13) 0.06
Family history of CVD 25.2 8.6 1.03 (0.94-1.13) 0.6
Risk factor control
Blood pressure <140/90 (mmHg) 89.9 74.3 0.32 (0.12-0.87) 0.02
LDL cholesterol <1.8 (mmol/l) 5.6 0 1.03 (0.88-1.21) 0.7
CVD drugs
Antihypertensives 10.0 28.6 3.56 (1.35-9.41) 0.01
Statins 6.4 20.0 3.64 (1.17-11.36) 0.02
RA characteristics
Age at disease onset (years) 34.4 (11.0) 43.3 (11.2) 1.08 (1.04-1.13) 0.0002
Duration (years) 5.5 (0.3-31.8) 4.8 (0.3-39.0) 1.01 (0.96-1.06) 0.6
RF and/or anti-CCP positive 60.6 45.7 0.55 (0.25-1.19) 0.1
Disease Activity Score in 28 joints 3.9 (4.7) 4.3 (7.3) 1.10 (0.82-1.48) 0.5
Joint erosion(s) 35.2 31.4 1.03 (0.87-1.24) 0.7
Extra-articular disease 15.6 14.3 0.79 (0.27-2.32) 0.7
C-reactive protein (mg/l) 1.0 (0.2-37.0) 1.0 (0.2-65.0) 1.02 (0.97-1.07) 0.4
Erythrocyte sedimentation rate (mm/hr) 10 (1-39) 8 (2-54) 1.00 (0.97-1.04) 0.8
Disease-modifying agents
Synthetic
Current use 97.2 100 2.55 (0.22-29.65) 0.5
Number ever used 2 (0-5) 2 (1-7) 1.46 (1.08-1.98) 0.01
Biologic
Current use 42.2 34.3 0.72 (0.32-1.59) 0.4
Number ever used 0.6 (0.9) 0.8 (1.5) 1.15 (0.82-1.63) 0.4
Prednisone use ever 76.1 94.3 5.17 (1.15-23.32) 0.03
NSAID use ever 93.6 88.6 0.53 (0.44-1.96) 0.3
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Table 1 Recorded characteristics and their associations with plaque in 144 patients with a SCORE of zero (Continued)
Plaque
Characteristics Absent Present
(n = 94) (n = 19) OR (95% CI) P
EULAR modifier 1.1 (0.8) 0.9 (0.9) 0.80 (0.50-1.29) 0.4
Components*
N = 0 24.8 40.0
N = 1 49.5 31.5
N = 2 20.2 20.0
N = 3 5.5 8.5
*Components include disease duration >10 years, rheumatoid factor or/and anti-cyclic citrullinated peptide positivity or/and extra-articular manifestations. Results
are expressed as mean (SD), median (range) or proportion as appropriate. Data were analyzed in logistic regression models. Bold P values are significant SCORE,
Systematic COronary Evaluation Score; n, number; OR, odds ratio; CI, confidence interval; CV, cardiovascular; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; CVD, cardiovascular disease; RA, rheumatoid arthritis; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; NSAID, nonsteroidal anti-inflammatory
drug; EULAR, European League Against Rheumatism.
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of EULAR modifier components was similar in patients
with and without carotid plaque; two or three components
were present in 28.5% and 25.2% of patients with and
without plaque, respectively.
Independent associations between recorded patient
characteristics and carotid plaque
Table 2 shows the recorded characteristics that were inde-
pendently related to plaque in a multivariable stepwise
backward conditional logistic regression model. Of the
seven characteristics entered into the model, two (systolic
blood pressure and antihypertensive agent use) were de-
leted by backward elimination. Age, the number of syn-
thetic DMARDs used and total cholesterol concentrations
were independently associated with plaque. The sensitiv-
ity, specificity, positive and negative predictive value andTable 2 Multivariable stepwise backward conditional
logistic regression model for plaque
Characteristic OR (95% CI) P
Age 1.15 (1.07-1.24) <0.0001
Number of synthetic DMARDs used 1.51 (1.05-2.17) 0.03
Total cholesterol 1.66 (1.00-2.74) 0.04
Statin use 3.55 (0.93-13.52) 0.06




Positive predictive value, % 66.7
Negative predictive value, % 85.5
Correct prediction, % 81.9
The variables systolic blood pressure and antihypertensive agent use were
deleted by backward elimination.
OR, odds ratio; CI, confidence interval; DMARDs, disease-modifying
antirheumatic drugs.correct prediction of the model were 51.4%, 91.7%, 66.7%,
85.5% and 81.9%, respectively. Replacement of the variable
systolic blood pressure by hypertension in the model given
in Table 2 did not alter the findings (data not shown).
As shown in Figure 2, to estimate the accuracy of age
and total cholesterol concentrations in predicting plaque
presence, we performed ROC curve analysis. The AUC
of the ROC curve was strongly associated with plaque
for both characteristics (0.807 (P <0.0001) and 0.679
(P = 0.001), respectively).
To determine the optimal cutoff values for age and
total cholesterol concentrations in determining plaque
presence amongst patients not treated with cardiovascular
drugs, we calculated the Youden index [17]. The obtained
values and their corresponding sensitivity, specificity, posi-
tive and negative predictive values (as calculated from
Bayes’ theorem [18]) are given in Table 3. The sensitivity,
specificity and negative predictive value were 74%, 75%
and 90% for age >49.5 years, and 63%, 70% and 86% for
total cholesterol concentrations >5.4 mmol/l, respectively.
The low positive predictive values obtained in the
current analysis (24% and 22% for age and total cholesterol,
respectively) are expected as the overall plaque prevalence
was, despite being clinically relevant, nevertheless numeric-
ally small at 24.3%. Further, this prevalence increased to
37.5% in patients (n = 80; 55.6%) with age or/and total
cholesterol concentration of >49.5 years and 5.4 mmol/l,
respectively; by contrast, the carotid plaque prevalence was
only 7.8% in those (n = 64; 44.4%) with age or/and total
cholesterol concentration of ≤49.5 years and 5.4 mmol/l,
respectively.
Figure S1 in Additional file 1 shows the ROC analysis
for the number of synthetic DMARDs used-carotid plaque
relation. In contrast to age and total cholesterol concentra-
tions, the number of synthetic DMARDs used was not sig-
nificantly related to plaque in ROC analysis (AUC= 0.599
and corresponding P value = 0.08). The optimal cutoff
Figure 2 Receiver operating characteristic (ROC) curves for predicting plaque presence by age and total cholesterol concentrations.
P values are given for the area under the curve (AUC)-plaque relations.
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positive and negative predictive value were therefore
not evaluated.
Discussion
In this study, approximately one in four women with RA
and a low predicted cardiovascular event rate as deter-
mined by SCORE, sustained atherosclerotic disease that
represents very high CVD risk. In the population at
large, men experience CVD events at a younger age than
women, which is accounted for in the SCORE equation
[8]. Congruently, 96% of our RA patients with a low cal-
culated risk as estimated by SCORE were women. None
of the six participating men had carotid plaque. Our
findings show that low CVD risk as estimated by SCORE
does not necessarily translate into absent high-risk ath-
erosclerosis in women with RA. This supports recently
reported evidence toward the need for improved CVD
risk stratification in RA [3,4,6,7,11,12,15,19].
Our results indicate that among women with RA that
are at low estimated CVD risk according to the SCORE,
consideration of age and total cholesterol concentrations
is useful in determining which of these patients experience
high-risk subclinical atherosclerosis. Indeed, age >49.5 yearsTable 3 Optimal cutoff values for age and total
cholesterol concentrations in ROC curves with
corresponding characteristics amongst RA patients
Characteristics Cutoff Sensitivity Specificity PPV NPV
Value (%) (%) (%) (%)
Age (years) 49.5 74 75 24 90
Total cholesterol (mmol/l) 5.4 63 70 22 86
ROC, receiver operating characteristic; RA, rheumatoid arthritis; PPV, positive
predictive value; NPV, negative predictive value.and total cholesterol concentrations of >5.4% predicted
plaque presence with a sensitivity and negative predictive
value of 74% and 63% and 90% and 86%, respectively.
Among patients aged >49.5 years or/and a total cholesterol
concentration of >5.4 mmol/l, more than one-third had
carotid plaque. Carotid artery plaque is independently as-
sociated with incident cardiovascular event rates amongst
patients with RA. Whether incorporation of carotid ultra-
sound findings in CVD risk stratification strategies among
RA patients with a low predicted CVD risk by SCORE,
and particularly those aged >49.5 years or/and a total
cholesterol concentration of >5.4 mmol/l, can reduce
future cardiovascular event rates, should be assessed in
future studies.
Persons that are at very high CVD risk as evidenced
by carotid ultrasound-determined plaque presence, re-
quire intensive cardiovascular risk management [8]. In-
deed, the LDL cholesterol target is <1.8 mmol/l in such
cases [8]. In the present investigation, none of the patients
with carotid plaque experienced adequate lipid control. In
addition, 25.7% of our patients with carotid plaque had in-
adequate blood pressure control, a value that was larger
than that in those without subclinical high-risk athero-
sclerosis, that is, 10.1%. Taken together, whereas the need
for tight disease activity control has been amply docu-
mented, our findings also stress the notion that more
stringent CVD risk factor control is required in at least a
clinically relevant proportion of patients with RA that are
at low estimated CVD risk according to SCORE.
RA characteristics or non-traditional rather than trad-
itional CVD risk factors are reportedly most strongly as-
sociated with atherosclerosis in young patients with RA
[12]. This contrasts to our findings, particularly among rela-
tively young women with RA, as age and total cholesterol
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consistently associated with plaque. This discrepancy could
be due to rigorous RA activity control in the present cohort
as the mean 28-item Disease Activity Score (DAS28) was
within the range for low disease activity at 3.1 [20].
In this study, we report for the first time on potential
predictors of plaque presence in patients with RA that
are at low estimated CVD risk according to SCORE. Of
interest in the present context, even amongst non-RA
subjects, recent investigations have revealed a prevalence
of carotid plaque as large as 34 to 59% despite an overall
low estimated CVD risk as determined by the Framing-
ham score [21,22]. Additionally, approximately 40% of
persons with a low SCORE were found to experience mul-
tidetector computed tomography-determined coronary ar-
tery plaque that was further also related to traditional
CVD risk factors [23].
Arts and colleagues [24] recently found that women
with RA have disease activity-related reduced HDL-2
subfraction levels, which are reportedly more closely
associated with CVD risk than total HDL cholesterol
concentrations [25]. The role of decreased HDL-2 produc-
tion in atherosclerosis among women with RA that have a
low calculated risk as estimated by SCORE should be the
subject of future studies.
Our data were derived from a single center and in
white patients only. The findings in the present investi-
gation require and merit validation in other population
groups. In this regard, the prevalence of seropositivity
for rheumatoid factor and anti-cyclic citrullinated pep-
tide antibody was relatively low at 56.9%, which may
have contributed to the lack of association of RA charac-
teristics with carotid plaque. Notably also, at the time of
our previous investigation on 370 consecutive patients
[11], the plaque prevalence was only 13% amongst those
with a SCORE value of zero. Upon investigating an add-
itional 180 patients (see Figure 1 in the present manu-
script), the respective prevalence has increased nearly
twofold. We are uncertain why this occurred as our re-
cruitment strategies have not been altered over time.
Whereas the main purpose of the present study was to
identify potential predictors of high-risk atherosclerosis
in patients with low estimated CVD risk by SCORE, the
increase in plaque prevalence over time among the re-
spective cases in our setting nevertheless further rein-
forces the need for external validation.Conclusions
Approximately one-third of women with RA who experi-
ence a low SCORE value and are aged >49.5 years or/and
have a total cholesterol concentration of >5.4 mmol/l ex-
perience high-risk atherosclerosis that requires intensive
CVD risk management.Additional file
Additional file 1: Figure S1. Receiver operating characteristic (ROC)
curves for predicting plaque presence by the number of disease-modifying
agents used. P values are given for the area under the curve (AUC)-plaque
relations.
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